|
Hot Stocks
| ShowHide Related Items >><< - 09:47 Today
- N-able rises 13.8%
- 03/28/23
- N-able to replace iStar in S&P 600 at open on 4/3
- 01/24/23 JPMorgan
- N-able assumed with Neutral from Overweight at JPMorgan
- 12/12/22 RBC Capital
- Coupa Software upgraded to Sector Perform from Underperform at RBC Capital
- 06/16/22 JPMorgan
- N-able price target lowered to $13 from $15 at JPMorgan
- 02/23/23
- N-able sees FY23 revenue $408M-$412M, consensus $397.3M
- 02/23/23
- N-able sees Q1 revenue $97.5M-$98M, consensus $94.99M
- 02/23/23
- N-able reports Q4 EPS 10c, consensus 7c
- 11/10/22
- N-able sees FY22 revenue $369.3M-369.8M, consensus $370.95M
- 03/28/23
- Fly Intel: After-Hours Movers
|
|
General news
| ShowHide Related Items >><< - 03/22/23
- Senators Scott, Warren unveil bipartisan Fed oversight legislation
- 03/01/23
- Einhorn says investors should be 'bearish on stocks and bullish on inflation'
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/08/23
- Biden to propose 25% billionaire tax, Bloomberg says
- 03/07/23
- Powell tells Congress data from January partly reversed softening trends
- 01/30/23
- Fed likely to raise funds rate benchmark by quarter percentage point, WSJ says
- 03/22/23
- What You Missed On Wall Street On Wednesday
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 03/21/23
- What You Missed On Wall Street This Morning
- 03/08/23
- What You Missed On Wall Street On Wednesday
- 03/22/23
- Fed says 'additional policy firming may be appropriate'
|
|
Recommendations
| ShowHide Related Items >><< - $829.11 /
+3.485 (+0.42%) - 07:08 Today
- Regeneron announces EC approved Libtayo in combination with chemotherapy
- 03/28/23
- Immuneering appoints Harold Brakewood as CBO
- 03/28/23
- Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration
- 03/23/23
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- 11/15/22 Capital One
- Kodiak Sciences initiated with an Overweight at Capital One
- 11/10/22 Citi
- Kodiak Sciences price target lowered to $6 from $8 at Citi
- 08/09/22 Truist
- Kodiak Sciences price target raised to $15 from $10 at Truist
- 08/08/22 Citi
- Citi keeps Sell rating on Kodiak Sciences, ups target to $8 after BEACON success
- $829.11 /
+3.485 (+0.42%) - 06:56 Today BofA
- Regeneron price target raised to $650 from $605 at BofA
- 03/28/23 Erste Group
- Regeneron resumed with a Buy at Erste Group
- 03/27/23 SVB Securities
- SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead
- 03/27/23 SVB Securities
- Regeneron upgraded to Outperform from Market Perform at SVB Securities
- 03/28/23
- Kodiak Sciences reports Q4 EPS ($1.35), consensus ($1.52)
- 11/09/22
- Kodiak Sciences reports Q3 EPS ($1.47) with itemds, consensus ($1.77)
- $829.11 /
+3.485 (+0.42%) - 02/03/23
- Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03
- 02/02/23
- Notable companies reporting before tomorrow's open
- 02/02/23
- Notable companies reporting before tomorrow's open
- 01/09/23
- Regeneron sees about $1.5B in Q4 U.S. net product sales of Eylea
- $829.11 /
+3.485 (+0.42%) - 11/04/22
- Supreme Court to hear Amgen appeal in Repatha patent dispute, Bloomberg says
- 03/28/23
- Fly Intel: After-Hours Movers
- $829.11 /
+3.485 (+0.42%) - 03/28/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/27/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/24/23
- What You Missed On Wall Street On Friday
- 03/24/23
- What You Missed On Wall Street This Morning
- $829.11 /
+3.485 (+0.42%) - 03/23/23
- Early notable gainers among liquid option names on March 23rd
|
|
Earnings
| ShowHide Related Items >><< - 01/24/23
- Paychex appoints Theresa Payton to Board of Directors
- 12/28/22
- Paychex VP Gioja sells $1.6M in company shares
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 10/14/22
- Paychex names President and CEO John Gibson, Jr. to board
- 03/13/23 Barclays
- Paychex price target lowered to $105 from $110 at Barclays
- 01/17/23 Barclays
- Paychex downgraded to Underweight from Equal Weight at Barclays
- 01/03/23 Deutsche Bank
- Paychex price target lowered to $116 from $123 at Deutsche Bank
- 12/27/22 Evercore ISI
- Paychex price target lowered to $114 from $117 at Evercore ISI
- 08:39 Today
- Paychex sees FY23 EPS growth of of 13%-14%, consensu $4.24
- 08:36 Today
- Paychex reports Q3 EPS $1.29, consensus $1.24
- 03/28/23
- Notable companies reporting before tomorrow's open
- 03/28/23
- Notable companies reporting before tomorrow's open
- 12/10/22
- Microsoft, Arista among stocks that can survive a triple whammy, Barron's says
- 12/23/22
- What You Missed On Wall Street On Friday
- 12/23/22
- What You Missed On Wall Street This Morning
- 12/22/22
- What You Missed On Wall Street On Thursday
- 12/22/22
- What You Missed On Wall Street This Morning
- 09:55 Today
- Early notable gainers among liquid option names on March 29th
|
|
Hot Stocks
| ShowHide Related Items >><< - 09:46 Today
- Ambit Biosciences Corp trading halted, volatility trading pause
- 03/20/23
- Ambit Biosciences Corp trading resumes
- 03/20/23
- Ambit Biosciences Corp trading halted, volatility trading pause
- 03/15/23
- Ambit Biosciences Corp trading resumes
|
|
On The Fly
|
Want to get stock-moving… ShowHide Related Items >><< - 02/21/23
- Bath & Body Works appoints Hershey CFO Voskuil to board
- 12/07/22
- Hershey announces first bilingual manufacturing facility
- 10/20/22
- Hershey signs new solar power purchase agreement with National Grid Renewables
- 03/27/23
- Carnival CEO says 'well booked for the remainder of the year at higher prices'
- 03/27/23
- Carnival ends Q1 with $8.1B of liquidity
- 01/27/23
- Salesforce appoints three new independent directors to board
- 01/18/23
- Carnival expands next-generation wi-fi connectivity with SpaceX's Starlink
- $366.74 /
+46.37 (+14.47%) - 03/28/23
- Lululemon jumps 9% to $348.97 after Q4 results, FY23 guidance beat estimates
- 01/12/23
- lululemon teams with Nedap to advance RFID technology across stores
- 01/09/23
- Lululemon falls 14% to $282.02 after revising Q4 guidance
- 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 03/08/23
- Marathon Petroleum acquires 49.9% stake in emerging LF Bioenergy
- 02/14/23
- Elliott buys NiSource, cuts Aerojet in Q4
- 01/31/23
- Marathon Petroleum sees FY23 capital spending $1.3B
- 01/24/23
- Marathon Petroleum trading resumes
- 03/20/23
- Foot Locker focusing on banners, geographies that will drive growth, says CEO
- 03/20/23
- Foot Locker to close stores, ecommerce in Hong Kong, Macau
- 11/29/22
- Foot Locker announces leadership team appointments
- 11/18/22
- Foot Locker rises 14.7%
- 07:07 Today
- Macy's announces CFO Adrian Mitchell to assume COO role as well
- 07:04 Today
- Macy's CEO Jeff Gennette to retire, Tony Spring to succeed
- 03/14/23
- Macy's launches expanded Reebok assortment in stores, online
- 03/02/23
- Macy's rises 10.0%
- 03/06/23
- Ciena expects to repurchase $250M shares this FY
- 03/06/23
- Ciena sees inventory lower in 4Q23 vs. 4Q22
- 03/06/23
- Ciena on track to achieve three year revenue CAGR outlook of 10%-12%, says CEO
- 03/06/23
- Ciena CEO: WaveLogic 6 to support up to 1.6Tbps single carrier wavelengths
- 03/21/23
- Medtronic, Nvidia collaborate to build AI platform for medical devices
- 03/15/23
- Medtronic receives CE Mark for the Affera Mapping and Ablation System
- 03/06/23
- Medtronic's PulseSelect PFA System exceeds safety performance goal in trial
- 02/24/23
- Medtronic announces one-year data from ADAPT study of MiniMed 780G system
- 03/06/23
- Bath & Body Works announces appointment of Kuhn to board of directors
- 02/27/23
- Bath & Body Works calls Third Point's potential proxy contest 'misguided'
- 02/23/23
- Bath & Body Works taking enterprise-wide effort to reduce expenses
- 02/23/23
- Bath & Body Works responds to Third Point intent to nominate board candidates
- 02/17/23
- Stryker's Q Guidance System for cranial applications receives FDA clearance
- 02/13/23
- Stryker exec Menon sells 2,161 common shares
- 02/06/23
- Stryker CFO Boehnlein sells $6.8M in common stock
- 12/07/22
- Stryker raises quarterly dividend 7.9% to 7.5c per share
- 03/05/23
- Fly Intel: Top five weekend stock stories
- 02/22/23
- Deere raises dividend to $1.25 from $1.20 per share
- 02/17/23
- Deere sees raw material costs getting more favorable throughout 2023
- 02/17/23
- Deere doesn't see big increase in dealier inventory in 2023
- 03/15/23
- Insulet to replace SVB Financial in S&P 500 at open on 3/15
- 03/10/23
- Insulet to replace SVB Financial in S&P 500 at open on 3/15
- 03/10/23
- Insulet to replace SVB Financial in S&P 500
- 02/14/23
- Insulet acquires assets of Automated Glucose Control for $25M
- 01/05/23
- Zimmer Biomet to acquire Embody for $155M at closing
- 11/30/22
- NeuroOne Medical ships initial Zimmer Biomet order for Evo sEEG system
- 11/21/22
- Zimmer Biomet announces FDA 510(k) clearance of Persona OsseoTi Keel Tibia
- 11/05/22
- Zimmer Biomet announces one-year data from mymobility clinical study
- 03/21/23
- DexCom announces expanded coverage for G6 CGM System in Manitoba
- 03/13/23
- DexCom has no material exposure to developments at Silicon Valley Bank
- 03/06/23
- DexCom down more than 7% after FDA gives nod to Abbott CGM sensors
- 03/02/23
- DexCom CEO sells $4.23M in common stock
- 06:26 Today Wells Fargo
- Hershey upgraded to Equal Weight on pricing tailwinds at Wells Fargo
- 05:14 Today Wells Fargo
- Hershey upgraded to Equal Weight from Underweight at Wells Fargo
- 03/27/23 Mizuho
- Hershey price target raised to $235 from $222 at Mizuho
- 03/23/23 Evercore ISI
- Hershey price target raised to $255 from $250 at Evercore ISI
- 07:25 Today Susquehanna
- Susquehanna upgrades Carnival with liquidity concerns 'effectively de-risked'
- 06:03 Today Susquehanna
- Carnival upgraded to Positive from Neutral at Susquehanna
- 03/28/23 Stifel
- Stifel believes setup for Carnival's shares is 'overly compelling'
- 03/28/23 Barclays
- Carnival price target raised to $13 from $12 at Barclays
- 06:11 Today BofA
- Nextracker upgraded to Buy from Neutral at BofA
- 03/22/23 Craig-Hallum
- Craig-Hallum bullish on Nextracker, initiates with a Buy
- 03/22/23 Craig-Hallum
- Nextracker initiated with a Buy at Craig-Hallum
- 03/06/23 Scotiabank
- Nextracker initiated with an Outperform, $38 price target at Scotiabank
- $366.74 /
+46.37 (+14.47%) - 09:20 Today BMO Capital
- Lululemon price target raised to $340 from $304 at BMO Capital
- 07:58 Today Jefferies
- Lululemon concerns 'haven't gone away' after Q4 report, says Jefferies
- 07:30 Today TD Cowen
- Lululemon price target raised to $500 from $470 at TD Cowen
- 07:20 Today Baird
- Lululemon price target raised to $425 from $410 at Baird
- 04:58 Today Goldman Sachs
- Marathon Petroleum upgraded to Buy from Neutral at Goldman Sachs
- 03/28/23 JPMorgan
- Marathon Petroleum downgraded to Neutral from Overweight at JPMorgan
- 03/10/23 Mizuho
- Marathon Petroleum upgraded to Buy from Neutral at Mizuho
- 03/08/23 UBS
- UBS starts eight independent refiners with three Buys
- 08:40 Today UBS
- Foot Locker downgraded to Sell at UBS on softlines bearishness
- 06:17 Today UBS
- Foot Locker downgraded to Sell from Neutral at UBS
- 03/21/23 Deutsche Bank
- Foot Locker price target raised to $42 from $36 at Deutsche Bank
- 03/21/23 Morgan Stanley
- Morgan Stanley 'skeptical' of 'show-me' story Foot Locker's long-term targets
- 06:31 Today Gordon Haskett
- Gordon Haskett downgrades Macy's on moderating foot traffic trends
- 06:26 Today Gordon Haskett
- Macy's downgraded to Hold from Accumulate at Gordon Haskett
- 03/03/23 TD Cowen
- Macy's price target raised to $29 from $27 at TD Cowen
- 02/23/23 Citi
- Macy's price target raised to $23 from $22 at Citi
- 04:52 Today Morgan Stanley
- Ciena downgraded to Equal Weight from Overweight at Morgan Stanley
- 03/28/23 Raymond James
- Ciena added to Analyst Current Favorites List at Raymond James
- 03/28/23 Raymond James
- Ciena upgraded to Strong Buy from Outperform at Raymond James
- 03/07/23 B. Riley
- Ciena price target raised to $72 from $69 at B. Riley
- 08:47 Today UBS
- Medtronic assumed with a Sell at UBS
- 03/28/23 UBS
- Medtronic assumed at Sell from Buy at UBS
- 03/28/23 UBS
- Medtronic downgraded to Sell from Buy at UBS
- 03/08/23 Wells Fargo
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- 08:38 Today UBS
- Bath & Body Works downgraded to Neutral at UBS on softlines bearishness
- 06:19 Today UBS
- Bath & Body Works downgraded to Neutral from Buy at UBS
- 03/23/23 Piper Sandler
- Bath & Body Works price target lowered to $48 from $52 at Piper Sandler
- 03/17/23 Argus
- Bath & Body Works cut to Hold at Argus on online competition, slowing sales
- 08:55 Today UBS
- Stryker initiated with a Neutral at UBS
- 03/28/23 UBS
- Stryker initiated with a Neutral at UBS
- 02/21/23 Argus
- Stryker price target raised to $285 from $270 at Argus
- 02/02/23 Barclays
- Stryker price target raised to $283 from $265 at Barclays
- 06:04 Today Daiwa
- Deere initiated with an Outperform at Daiwa
- 05:22 Today Daiwa
- Deere initiated with an Outperform at Daiwa
- 02/21/23 Argus
- Deere price target raised to $485 from $475 at Argus
- 02/21/23 Morgan Stanley
- Deere price target raised to $537 from $522 at Morgan Stanley
- 08:35 Today UBS
- Insulet initiated with a Neutral at UBS
- 03/28/23 UBS
- Insulet initiated with a Neutral at UBS
- 02/24/23 Raymond James
- Insulet price target raised to $334 from $320 at Raymond James
- 02/24/23 Baird
- Insulet price target raised to $350 from $340 at Baird
- 08:39 Today UBS
- Zimmer Biomet initiated with a Sell at UBS
- 03/28/23 UBS
- Zimmer Biomet initiated with a Sell at UBS
- 03/10/23 Piper Sandler
- Zimmer upgraded to Overweight on 'conservative' outlook at Piper Sandler
- 03/09/23 Piper Sandler
- Zimmer Biomet upgraded to Overweight from Neutral at Piper Sandler
- 08:41 Today UBS
- DexCom initiated with a Buy at UBS
- 03/28/23 UBS
- DexCom initiated with a Buy at UBS
- 03/27/23 Jefferies
- DexCom Q1 report can be a catalyst for shares, says Jefferies
- 03/08/23 Jefferies
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
- 03/22/23
- Hershey backs FY23 adjusted EPS growth view 9%-11%, consensus $9.35
- 02/02/23
- Hershey sees FY23 adjusted EPS up 9%-11%, consensus $8.94
- 02/02/23
- Hershey reports Q4 adjusted EPS $2.02, consensus $1.77
- 02/01/23
- Notable companies reporting before tomorrow's open
- 03/27/23
- Carnival sees Q2 adjusted EBITDA $600M-$700M
- 03/27/23
- Carnival sees FY23 adjusted EBITDA $3.9B-$4.1B
- 03/27/23
- Carnival sees FY23 adjusted EPS (44c)-(28c), consensus (8c)
- 03/27/23
- Carnival sees Q2 adjusted EPS (42c)-(34c), consensus (28c)
- $366.74 /
+46.37 (+14.47%) - 03/28/23
- Lululemon sees FY23 EPS $11.50-$11.72, consensus $11.26
- 03/28/23
- Lululemon sees Q1 EPS $1.93-$2.00, consensus $1.64
- 03/28/23
- Lululemon reports Q4 adjusted EPS $4.40, consensus $4.26
- 03/28/23
- Notable companies reporting after market close
- 01/31/23
- Marathon Petroleum reports Q4 adjusted EPS $6.65, consensus $5.67
- 11/01/22
- Marathon Petroleum reports Q3 EPS $7.81, consensus $6.95
- 03/20/23
- Foot Locker targeting adjusted EPS growth in low to mid 20% range for FY24-FY26
- 03/20/23
- Foot Locker sees FY23 adjusted EPS $3.35-$3.65, consensus $4.48
- 03/20/23
- Foot Locker reports Q4 adjusted EPS 97c, consensus 51c
- 11/18/22
- Foot Locker raises FY22 EPS view to $4.42-$4.50 from $4.25-$4.45
- 03/02/23
- Macy's sees Q1 adjusted EPS 42c-48c, consensus 72c
- 03/02/23
- Macy's sees FY23 adjusted EPS $3.67-$4.11, consensus $3.84
- 03/02/23
- Macy's reports Q4 adjusted EPS $1.88, consensus $1.57
- 03/01/23
- Notable companies reporting before tomorrow's open
- 03/06/23
- Ciena now sees FY23 revenue up 20%-22% y/y, up from 16%-18% y/y
- 03/06/23
- Ciena sees Q2 revenue $1.035B-$1.115B, consensus $1.04B
- 03/06/23
- Ciena reports Q1 adjusted EPS 64c, consensus 36c
- 12/08/22
- Ciena sees Q1 revenue $910M-$990M, consensus $871.03M
- 02/21/23
- Medtronic sees Q4 EPS $1.55-$1.57, consensus $1.58
- 02/21/23
- Medtronic narrows FY23 EPS view to $5.28-$5.30 from $5.25-$5.30
- 02/21/23
- Medtronic reports Q3 EPS $1.30, consensus $1.27
- 11/22/22
- Medtronic sees Q3 adjusted EPS $1.25-$1.27, consensus $1.40
- 02/23/23
- Bath & Body Works sees FY23 cont ops EPS $2.50-$3.00, consensus $3.16
- 02/23/23
- Bath & Body Works sees Q1 cont ops EPS 17c-27c, consensus 44c
- 02/23/23
- Bath & Body Works reports Q4 cont ops EPS $1.86, consensus $1.62
- 02/22/23
- Notable companies reporting before tomorrow's open
- 01/31/23
- Stryker sees FY23 adjusted EPS $9.85-$10.15, consensus $9.86
- 01/31/23
- Stryker reports Q4 adjusted EPS $3.00, consensus $2.84
- 10/31/22
- Stryker reports Q3 adjusted EPS $2.12, consensus $2.23
- 10/31/22
- Notable companies reporting after market close
- 02/17/23
- Deere sees FY23 net income $8.75B-$9.25B, effective tax rate 23%-25%
- 02/17/23
- Deere reports Q1 EPS $6.55, consensus $5.56
- 02/16/23
- Notable companies reporting before tomorrow's open
- 02/16/23
- Notable companies reporting before tomorrow's open
- 02/23/23
- Insulet sees FY23 revenue growth 14%-19%, consensus $1.47B
- 02/23/23
- Insulet sees Q1 revenue growth 11%-14%, consensus $333.86M
- 02/23/23
- Insulet reports Q4 adjusted EPS 55c, consensus 21c
- 11/03/22
- Insulet raises FY22 revenue growth view to 18%-19% from 14%-17%
- 02/03/23
- Zimmer Biomet sees FY23 adjusted EPS $6.95-$7.15, consensus $6.98
- 02/03/23
- Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83
- 02/02/23
- Notable companies reporting before tomorrow's open
- 02/02/23
- Notable companies reporting before tomorrow's open
- 02/09/23
- DexCom sees FY23 revenue of $3.35B-$3.49B, consensus $3.47B
- 02/09/23
- DexCom reports Q4 EPS 22c, consensus 27c
- 02/09/23
- Notable companies reporting after market close
- 01/09/23
- DexCom sees Q revenue $2.91B, consensus $2.9B
|
|
Options
| ShowHide Related Items >><< - 03/27/23
- First Republic rises 15.5%
- 03/27/23
- First Republic rises 22.8%
- 03/27/23
- First Republic rises 25.0%
- 03/26/23
- Fly Intel: Top five weekend stock stories
- 03/28/23
- Micron says now expects overall headcount reduction to approach 15%
- 03/28/23
- Micron says further reducing supply
- 03/28/23
- Micron up 2% after Q2 report
- 03/02/23
- Micron down 3% in pre-market as CFO presents at conference
- $465.00 /
+21.49 (+4.85%) - 12/16/22
- Cintas launches electric vehicle pilot program
- 11/15/22
- Cintas expands cleanroom footprint with new facility in New York
- 03/27/23
- Carnival CEO says 'well booked for the remainder of the year at higher prices'
- 03/27/23
- Carnival ends Q1 with $8.1B of liquidity
- 01/27/23
- Salesforce appoints three new independent directors to board
- 01/18/23
- Carnival expands next-generation wi-fi connectivity with SpaceX's Starlink
- 01/24/23
- Paychex appoints Theresa Payton to Board of Directors
- 12/28/22
- Paychex VP Gioja sells $1.6M in company shares
- 12/11/22
- Fly Intel: Top five weekend stock stories
- 10/14/22
- Paychex names President and CEO John Gibson, Jr. to board
- 03/23/23 Citi
- Citi withdraws Neutral rating on First Republic
- 03/21/23 Goldman Sachs
- First Republic rating suspended at Goldman Sachs
- 03/20/23 Evercore ISI
- Evercore ISI suspends rating on First Republic in light of uncertainty
- 03/20/23 Morgan Stanley
- Morgan Stanley removes First Republic price target amid 'wide range of outcomes'
- 09:02 Today Needham
- Micron price target raised to $71 from $67 at Needham
- 07:38 Today Susquehanna
- Micron price target raised to $90 from $65 at Susquehanna
- 07:29 Today TD Cowen
- Micron price target raised to $70 from $66 at TD Cowen
- 07:27 Today Baird
- Micron price target raised to $60 from $45 at Baird
- $465.00 /
+21.49 (+4.85%) - 12/22/22 Wells Fargo
- Cintas price target raised to $450 from $393 at Wells Fargo
- 12/22/22 Deutsche Bank
- Cintas price target raised to $507 from $490 at Deutsche Bank
- 12/22/22 Baird
- Cintas price target raised to $500 from $475 at Baird
- 12/22/22 Morgan Stanley
- Cintas price target raised to $401 from $373 at Morgan Stanley
- 07:25 Today Susquehanna
- Susquehanna upgrades Carnival with liquidity concerns 'effectively de-risked'
- 06:03 Today Susquehanna
- Carnival upgraded to Positive from Neutral at Susquehanna
- 03/28/23 Stifel
- Stifel believes setup for Carnival's shares is 'overly compelling'
- 03/28/23 Barclays
- Carnival price target raised to $13 from $12 at Barclays
- 03/13/23 Barclays
- Paychex price target lowered to $105 from $110 at Barclays
- 01/17/23 Barclays
- Paychex downgraded to Underweight from Equal Weight at Barclays
- 01/03/23 Deutsche Bank
- Paychex price target lowered to $116 from $123 at Deutsche Bank
- 12/27/22 Evercore ISI
- Paychex price target lowered to $114 from $117 at Evercore ISI
- 01/13/23
- First Republic reports Q4 EPS $1.88, consensus $1.80
- 01/12/23
- Notable companies reporting before tomorrow's open
- 01/12/23
- Notable companies reporting before tomorrow's open
- 10/14/22
- First Republic reports Q3 EPS $2.21, consensus $2.18
- 03/28/23
- Micron sees Q3 adjusted EPS ($1.65)-($1.51), consensus (90c)
- 03/28/23
- Micron reports Q2 adjusted EPS ($1.91), consensus (86c)
- 03/28/23
- Notable companies reporting after market close
- 03/02/23
- Micron sees lower margins in fiscal Q3 than previously expected
- $465.00 /
+21.49 (+4.85%) - 08:46 Today
- Cintas reports Q3 EPS $3.14, consensus $3.04
- 08:41 Today
- Cintas raises FY23 EPS view to $12.70-$12.90 from $12.50-$12.80
- 08:37 Today
- Cintas reports Q4 EPS $3.14, consensus $3.04
- 12/21/22
- Cintas raises FY23 EPS view to $12.50-$12.80 from $12.30-$12.65
- 03/27/23
- Carnival sees Q2 adjusted EBITDA $600M-$700M
- 03/27/23
- Carnival sees FY23 adjusted EBITDA $3.9B-$4.1B
- 03/27/23
- Carnival sees FY23 adjusted EPS (44c)-(28c), consensus (8c)
- 03/27/23
- Carnival sees Q2 adjusted EPS (42c)-(34c), consensus (28c)
- 08:39 Today
- Paychex sees FY23 EPS growth of of 13%-14%, consensu $4.24
- 08:36 Today
- Paychex reports Q3 EPS $1.29, consensus $1.24
- 03/28/23
- Notable companies reporting before tomorrow's open
- 03/28/23
- Notable companies reporting before tomorrow's open
|
|
Hot Stocks
| ShowHide Related Items >><< EBS Emergent BioSolutions - 09:50 Today
- Emergent BioSolutions: FDA approves OTC designation for Narcan Nasal Spray
- 09:47 Today
- Emergent BioSolutions rises 17.5%
- 09:06 Today
- Emergent jumps 19% to $10.60 after FDA approves over-the-counter Narcan
- 09:05 Today
- FDA approves Emergent's Narcan for over-the-counter use
EBS Emergent BioSolutions - 03/17/23 JPMorgan
- Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
- 12/28/22 Benchmark
- Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
- 11/10/22 Benchmark
- Benchmark downgrades Emergent on delay in smallpox vaccine fulfillment
- 11/10/22 Benchmark
- Emergent BioSolutions downgraded to Hold from Buy at Benchmark
EBS Emergent BioSolutions - 02/27/23
- Emergent BioSolutions sees FY23 revenue $1.1B-$1.2B, consensus $1.18B
- 02/27/23
- Emergent BioSolutions sees Q1 revenue $130M-$150M, consensus $245.9M
- 02/27/23
- Emergent BioSolutions reports Q4 EPS (31c), consensus 4c
- 01/09/23
- Emergent reports preliminary FY22 revenue $1.1B-$1.12B, consensus $1.09B
EBS Emergent BioSolutions - 02/15/23
- Fly Intel: After-Hours Movers
- 02/15/23
- Fly Intel: Pre-market Movers
- 01/05/23
- Fly Intel: After-Hours Movers
- 11/11/22
- Biotech Alert: Searches spiking for these stocks today
|
|
Recommendations
|
DA Davidson analyst Matt… ShowHide Related Items >><< - $107.75 /
+0.665 (+0.62%) - 03/14/23
- Crane announces Paul Igoe appointed General Counsel of Crane NXT
- 03/08/23
- Crane announces timing of previously announced separation
- 02/07/23
- Crane announces effectiveness of Form 10 for Crane Company
- 10/20/22
- Crane names Aaron Saak CEO of Crane NXT
- $107.75 /
+0.665 (+0.62%) - 03/24/23 UBS
- Crane downgraded to Neutral into NXT separation at UBS
- 03/24/23 UBS
- Crane downgraded to Neutral from Buy at UBS
- 01/25/23 DA Davidson
- Crane price target raised to $140 from $130 at DA Davidson
- 12/12/22 Morgan Stanley
- Crane upgraded to Overweight from Equal Weight at Morgan Stanley
- $107.75 /
+0.665 (+0.62%) - 01/23/23
- Crane sees FY23 EPS $3.40-$3.70 post separation
- 01/23/23
- Crane reports Q4 EPS $2.13, consensus $1.90
- 10/24/22
- Crane narrows FY22 EPS view to $7.58-$7.72 from $7.45-$7.85, consensus $7.75
- 10/24/22
- Crane reports Q3 adjusted EPS $1.86, consensus $1.85
- $107.75 /
+0.665 (+0.62%) - 03/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/23/23
- Fly Intel: After-Hours Movers
- 10/24/22
- Fly Intel: After-Hours Movers
|
|
Hot Stocks
|
Coeptis Therapeutics has… ShowHide Related Items >><< COEP Coeptis Therapeutics - 10/31/22
- Bull Horn Holdings closes combination with Coeptis Therapeutics
COEP Coeptis Therapeutics - 12/12/22 EF Hutton
- Coeptis Therapeutics initiated with a Buy at EF Hutton
|
